布拉氏酵母菌散联合美洛西林钠治疗感染性腹泻临床疗效及对患儿血清CRP、PCT和IL-8的影响

Clinical efficacy of Saccharomyces boulardii combined with mezlocillin in the treatment of children with infectious diarrhea and effect on serum CRP,PCT and IL-8

[目的]探讨布拉氏酵母菌散联合美洛西林钠治疗感染性腹泻临床疗效及对患儿血清C-反应蛋白(CRP)、降钙素原(PCT)和白介素-8(IL-8)的影响。[方法]选取2015年9月~2016年12月期间收治的134例感染性腹泻患儿,采用回顾性分析法对患儿的临床资料进行分析。将患儿按照不同治疗方式分成观察组与对照组(每组67例),对照组患儿采用美洛西林钠治疗;观察组患儿采用布拉氏酵母菌散联合美洛西林钠治疗。观察不同治疗方式治疗2组患儿临床疗效以及对血清CRP、PCT和IL-8的影响。[结果]观察组患儿总有效率为(95.52%),显著高于对照组(79.10%)(P<0.05);治疗前2组患儿血清CRP、PCT和IL-8变化情况比较差异无统计学意义,治疗后2组患儿血清CRP、PCT和IL-8表达水平均有下降,但是观察组患儿下降程度明显高于对照组(P<0.05);观察组患儿止泻时间以及治愈时间明显少于对照组(P<0.05);2组患儿不良反应情况比较差异无统计学意义。[结论]布拉氏酵母菌散联合美洛西林钠治疗感染性腹泻能提高临床治疗疗效,抑制患儿血清中相关炎性因子的表达水平,控制患儿的感染情况,且不良反应少,值得在临床上推广使用。

[Objective]To investigate the clinical efficacy of Saccharomyces boulardii combined with mezlocillin in the treatment of infectious diarrhea and its effect on serum CRP,PCT and IL-8 in children.[Methods]134 children with infectious diarrhea were selected from September 2015 to December 2016.The clinical data of children with infectious diarrhea were retrospectively analyzed.According to the different treatments,the children were divided into observation group and control group with 67 cases in each group.The children in the control group were treated with mezlocillin and the children in the observation group were treated with Saccharomyces boulardii powder combined with mezlocillin.The clinical effect of different treatment methods on two groups of children and their effect on the serum CRP,PCT and IL-8 were observed and compared.[Results]The total efficiency of the observation group was significantly higher than that in the control group（95.52% vs.79.10% ）（P0.05）.Before treatment,there were no difference in the levels of serum CRP,PCT and IL-8 between two groups（P0.05）.The serum CRP,PCT and IL-8 expression levels were both decreased in two groups after treatment,but the decline degree in the observation group was significantly higher than that in the control group（P0.05）.The antidiarrheal time and cure time in the observation group were significantly less than that in the control group（P0.05）.There was no difference about adverse reactions between two groups（P0.05）.[Conclusion]Saccharomy-ces boulardii combined with mezlocillin in the treatment of children with infectious diarrhea can improve the clinical curative effect,inhibit the expression level of inflammatory cytokines and control the infection with less adverse reaction in children,which is worth popularizing in clinical use.